Brooks Laboratories Limited (BROOKS.BO)
INR 162.3
(1.98%)
INR 162.3
(1.98%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 51.18 Million INR | -73.83% |
| 2022 | 348.09 Million INR | -3.3% |
| 2021 | 359.97 Million INR | 26.75% |
| 2020 | 284 Million INR | 14.06% |
| 2019 | 249 Million INR | 14.81% |
| 2018 | 216.88 Million INR | -11.12% |
| 2017 | 244 Million INR | 67.54% |
| 2016 | 145.63 Million INR | 10.58% |
| 2015 | 131.7 Million INR | -5.47% |
| 2014 | 139.32 Million INR | -5.88% |
| 2013 | 148.03 Million INR | 37.32% |
| 2012 | 107.8 Million INR | 38.9% |
| 2011 | 77.61 Million INR | 67.36% |
| 2010 | 46.37 Million INR | 51.14% |
| 2009 | 30.68 Million INR | 12.38% |
| 2008 | 27.3 Million INR | 8.01% |
| 2007 | 25.27 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 22.74 Million INR | -3.03% |
| 2023 Q1 | 19.23 Million INR | 130.68% |
| 2023 Q2 | 55.79 Million INR | 190.03% |
| 2023 Q3 | 56.26 Million INR | 0.84% |
| 2023 Q4 | 23.46 Million INR | -58.31% |
| 2023 FY | 91.09 Million INR | -73.83% |
| 2022 Q1 | 115.45 Million INR | 586.27% |
| 2022 Q2 | 148.49 Million INR | 28.61% |
| 2022 Q3 | 146.84 Million INR | -1.11% |
| 2022 Q4 | -62.7 Million INR | -142.7% |
| 2022 FY | 348.09 Million INR | -3.3% |
| 2021 FY | 359.97 Million INR | 26.75% |
| 2021 Q2 | 116.28 Million INR | 13.06% |
| 2021 Q4 | 16.82 Million INR | -86.55% |
| 2021 Q3 | 125.08 Million INR | 7.57% |
| 2021 Q1 | 102.85 Million INR | 185.58% |
| 2020 FY | 284 Million INR | 14.06% |
| 2020 Q1 | 70.79 Million INR | 765.94% |
| 2020 Q2 | 87.91 Million INR | 24.18% |
| 2020 Q3 | 89.54 Million INR | 1.86% |
| 2020 Q4 | 36.01 Million INR | -59.78% |
| 2019 Q4 | 8.17 Million INR | -90.62% |
| 2019 Q2 | 78.93 Million INR | 5.67% |
| 2019 Q3 | 87.18 Million INR | 10.45% |
| 2019 FY | 249 Million INR | 14.81% |
| 2019 Q1 | 74.7 Million INR | 1010.65% |
| 2018 Q3 | 76.63 Million INR | 2.2% |
| 2018 FY | 216.88 Million INR | -11.12% |
| 2018 Q2 | 74.98 Million INR | 1.41% |
| 2018 Q1 | 73.94 Million INR | -13.55% |
| 2018 Q4 | -8.2 Million INR | -110.7% |
| 2017 Q3 | 82.1 Million INR | 6.79% |
| 2017 Q1 | 72.18 Million INR | 35.04% |
| 2017 FY | 244 Million INR | 67.54% |
| 2017 Q4 | 85.52 Million INR | 4.17% |
| 2017 Q2 | 76.88 Million INR | 6.51% |
| 2016 FY | 145.63 Million INR | 10.58% |
| 2016 Q4 | 53.45 Million INR | 33.83% |
| 2016 Q3 | 39.94 Million INR | -4.79% |
| 2016 Q1 | 38.99 Million INR | -7.95% |
| 2016 Q2 | 41.94 Million INR | 7.57% |
| 2015 FY | 131.7 Million INR | -5.47% |
| 2015 Q3 | 38.69 Million INR | -5.73% |
| 2015 Q2 | 41.04 Million INR | 21.69% |
| 2015 Q1 | 33.72 Million INR | 20.24% |
| 2015 Q4 | 42.36 Million INR | 9.49% |
| 2014 Q1 | 25.5 Million INR | 591.31% |
| 2014 Q4 | 28.04 Million INR | -36.71% |
| 2014 FY | 139.32 Million INR | -5.88% |
| 2014 Q2 | 46.49 Million INR | 82.3% |
| 2014 Q3 | 44.31 Million INR | -4.68% |
| 2013 Q2 | 61.67 Million INR | 40.21% |
| 2013 Q4 | -5.19 Million INR | -110.92% |
| 2013 FY | 148.03 Million INR | 37.32% |
| 2013 Q3 | 47.54 Million INR | -22.9% |
| 2013 Q1 | 43.98 Million INR | 151.26% |
| 2012 Q3 | 40.2 Million INR | 24.84% |
| 2012 Q2 | 32.2 Million INR | 79.89% |
| 2012 Q4 | 17.5 Million INR | -56.46% |
| 2012 Q1 | 17.9 Million INR | -4.85% |
| 2012 FY | 107.8 Million INR | 38.9% |
| 2011 Q2 | 19.5 Million INR | 0.0% |
| 2011 Q4 | 18.81 Million INR | -17.49% |
| 2011 FY | 77.61 Million INR | 67.36% |
| 2011 Q3 | 22.8 Million INR | 16.92% |
| 2010 FY | 46.37 Million INR | 51.14% |
| 2009 FY | 30.68 Million INR | 12.38% |
| 2008 FY | 27.3 Million INR | 8.01% |
| 2007 FY | 25.27 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Ajanta Pharma Limited | 30.46 Billion INR | 99.832% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | 95.343% |
| Sigachi Industries Limited | 579.88 Million INR | 91.174% |
| Bal Pharma Limited | 389.89 Million INR | 86.873% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | 97.591% |
| Medico Remedies Limited | 161.84 Million INR | 68.377% |
| Lasa Supergenerics Limited | 291.17 Million INR | 82.423% |
| Venus Remedies Limited | 1.91 Billion INR | 97.329% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 98.337% |
| Alpa Laboratories Limited | 156.14 Million INR | 67.223% |
| Nectar Lifesciences Limited | 625.55 Million INR | 91.818% |
| Shilpa Medicare Limited | 2.18 Billion INR | 97.653% |
| Aarti Drugs Limited | 1.16 Billion INR | 95.616% |
| Lupin Limited | 95.67 Billion INR | 99.947% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 99.87% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 99.881% |
| Windlas Biotech Limited | 1 Billion INR | 94.915% |
| Suven Life Sciences Limited | 109.75 Million INR | 53.367% |
| Eris Lifesciences Limited | 4.94 Billion INR | 98.965% |
| Valiant Laboratories Limited | 36.28 Million INR | -41.034% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 99.392% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | 98.882% |
| Ipca Laboratories Limited | 13.91 Billion INR | 99.632% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | 96.394% |
| Achyut Healthcare Limited | 1.6 Million INR | -3080.858% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.967% |
| Bajaj HealthCare Limited | 985.34 Million INR | 94.806% |
| RPG Life Sciences Limited | 1.63 Billion INR | 96.871% |
| Mankind Pharma Limited | 23.15 Billion INR | 99.779% |
| Laurus Labs Limited | 3.01 Billion INR | 98.3% |
| Piramal Pharma Limited | 19.91 Billion INR | 99.743% |
| Syncom Formulations (India) Limited | 942.39 Million INR | 94.569% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 99.761% |
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 99.677% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 99.924% |
| Unichem Laboratories Limited | 6.72 Billion INR | 99.239% |
| Sequent Scientific Limited | 2.9 Billion INR | 98.236% |
| Novartis India Limited | 470.1 Million INR | 89.113% |
| Wanbury Limited | 1.16 Billion INR | 95.591% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | 96.352% |
| Wockhardt Limited | 6.4 Billion INR | 99.2% |
| Themis Medicare Limited | 782.85 Million INR | 93.462% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | 93.383% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 99.646% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 99.56% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.947% |
| Divi's Laboratories Limited | 14.17 Billion INR | 99.639% |
| NATCO Pharma Limited | 10.05 Billion INR | 99.491% |
| Gufic Biosciences Limited | 1.07 Billion INR | 95.251% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | 95.342% |
| Ind-Swift Limited | 946.56 Million INR | 94.593% |
| Procter & Gamble Health Limited | 2.99 Billion INR | 98.291% |
| FDC Limited | 5.34 Billion INR | 99.043% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -10.885% |
| Granules India Limited | 7.18 Billion INR | 99.287% |
| Medicamen Biotech Limited | 335.16 Million INR | 84.73% |
| Alkem Laboratories Limited | 32.83 Billion INR | 99.844% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | 98.032% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -215.737% |
| Megasoft Limited | 49.52 Million INR | -3.335% |
| ZIM Laboratories Limited | 1.01 Billion INR | 94.948% |
| Strides Pharma Science Limited | 9.16 Billion INR | 99.441% |
| Neuland Laboratories Limited | 2.92 Billion INR | 98.253% |
| Morepen Laboratories Limited | 1.98 Billion INR | 97.425% |
| Hikal Limited | 2.48 Billion INR | 97.942% |
| Indoco Remedies Limited | 4.74 Billion INR | 98.922% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 98.335% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | 87.591% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | 92.431% |
| Hester Biosciences Limited | 908.84 Million INR | 94.369% |